Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant TEC Chemotherapy in HER2-negative Primary Breast Cancer
DRKS00000162Phase 2Completed
- Sponsor
- Brustzentrum Leipzig
- Start
- Jul 2009
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, epirubicin and cyclophosphamide in breast cancer, sponsored by Brustzentrum Leipzig. Started Jul 2009; status: completed.
02
Drugs
docetaxelepirubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on DRKS00000162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00000162.